Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3.

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3.

Bibliographic Details
Main Author:	PLOS ONE Editors
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0267745

Similar Items

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
by: The Editors
Published: (2022-01-01)

Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.
by: Toni M Brand, et al.
Published: (2013-01-01)

Retraction: A Cross-Talk between TrkB and Ret Tyrosine Kinases Receptors Mediates Neuroblastoma Cells Differentiation.
by: PLOS ONE Editors
Published: (2022-01-01)

Determination of gene expression of tyrosine kinase receptors (HER family) in FFPE tissue of colorectal adenocarcinoma
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
by: Carla De Giovanni, et al.
Published: (2021-07-01)

Expression of Concern: HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis.
by: PLOS ONE Editors
Published: (2023-01-01)

Retraction: Epithelial-Mesenchymal Transition Markers and HER3 Expression Are Predictors of Elisidepsin Treatment Response in Breast and Pancreatic Cancer Cell Lines.
by: PLOS ONE Editors
Published: (2024-01-01)

Retraction: Plumbagin Suppresses the Invasion of HER2-Overexpressing Breast Cancer Cells through Inhibition of IKKα-Mediated NF-κB Activation.
by: PLOS ONE Editors
Published: (2019-01-01)

Retraction: DMA, a Bisbenzimidazole, Offers Radioprotection by Promoting NFκB Transactivation through NIK/IKK in Human Glioma Cells.
by: PLOS ONE Editors
Published: (2020-01-01)

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
by: Kong, A, et al.
Published: (2008)

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
by: Anthony Kong, et al.
Published: (2008-08-01)

Retraction: Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells.
by: PLOS ONE Editors
Published: (2019-01-01)

Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor.
by: Saghir Akhtar, et al.
Published: (2015-01-01)

Retraction: Interferon-β Induces Cellular Senescence in Cutaneous Human Papilloma Virus-Transformed Human Keratinocytes by Affecting p53 Transactivating Activity.
by: PLOS ONE Editors
Published: (2019-01-01)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
by: Zihong Wu, et al.
Published: (2023-03-01)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
by: Nathan Griffin, et al.
Published: (2020-09-01)

Retraction: Protein Tyrosine Phosphatase 1B and Insulin Resistance: Role of Endoplasmic Reticulum Stress/Reactive Oxygen Species/Nuclear Factor Kappa B Axis.
by: PLOS ONE Editors
Published: (2022-01-01)

ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity
by: Snježana Mikuličić, et al.
Published: (2024-02-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
by: Lu Yang, et al.
Published: (2022-06-01)

Expression of Concern: The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.
by: PLOS ONE Editors
Published: (2022-01-01)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
by: Ilana Schlam, et al.
Published: (2021-05-01)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
by: Desh Deepak Singh, et al.
Published: (2022-12-01)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
by: Xue Yang MSc, et al.
Published: (2020-10-01)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
by: PLOS ONE Staff
Published: (2020-01-01)

Corrigendum: ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity
by: Snježana Mikuličić, et al.
Published: (2024-02-01)

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
by: Ibrahim H. Kankia, et al.
Published: (2021-04-01)

Retraction: A Functional Nuclear Epidermal Growth Factor Receptor, Src and Stat3 Heteromeric Complex in Pancreatic Cancer Cells.
by: PLOS ONE Editors
Published: (2019-01-01)

Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology
by: Dayana Pérez-Martínez, et al.
Published: (2022-07-01)

Retraction: Outer Membrane Protein A (OmpA) of Shigella flexneri 2a Induces TLR2-Mediated Activation of B Cells: Involvement of Protein Tyrosine Kinase, ERK and NF-κB.
by: PLOS ONE Editors
Published: (2020-01-01)

Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
by: Daniela Miladinova
Published: (2023-03-01)

Retraction: Tyrosine Nitration of PA700 Links Proteasome Activation to Endothelial Dysfunction in Mouse Models with Cardiovascular Risk Factors.
by: PLOS ONE Editors
Published: (2023-01-01)

Retraction: Multi-Level Interactions between the Nuclear Receptor TRα1 and the WNT Effectors β-Catenin/Tcf4 in the Intestinal Epithelium.
by: PLOS ONE Editors
Published: (2020-01-01)

Retraction: Activation of the AMP-Activated Protein Kinase (AMPK) by Nitrated Lipids in Endothelial Cells.
by: PLOS ONE Editors
Published: (2020-01-01)

Retraction: Terminal drought and heat stress alter physiological and biochemical attributes in flag leaf of bread wheat.
by: PLOS ONE Editors
Published: (2023-01-01)

Retraction: SOX2 Enhances the Migration and Invasion of Ovarian Cancer Cells via Src Kinase.
by: PLOS ONE Editors
Published: (2023-01-01)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
by: Andreia Gameiro, et al.
Published: (2021-03-01)

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
by: Marie-Anne Goyette, et al.
Published: (2023-12-01)

SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells
by: Robert Jenke, et al.
Published: (2020-12-01)

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
by: Marie-Anne Goyette, et al.
Published: (2018-05-01)

Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.
by: PLOS ONE Editors
Published: (2019-01-01)